Tern Plc further re. FundamentalVR fund raise

Tern plc

Tern plc (LON:TERN) noted this morning that in the Company’s announcement dated 11 August 2022, the Company stated that FVRVS Limited (“FundamentalVR”) had closed a second tranche of its Series B fund raising round, securing an additional £5 million in new investment (the “FundamentalVR Series B second tranche”) from a new institutional investor at the same valuation as the first tranche, making a total of £13.2 million raised in Series B funding at this time.

The Company notes that in its press release dated 11 August 2022, FundamentalVR, an independent privately held company, stated that it “has raised an additional $20 million to significantly accelerate medical skill-transfer and increase surgical proficiency through its world-leading medical simulation platform, Fundamental Surgery.”

Tern plc can confirm that all the information disclosed in its announcement dated 11 August 2022 is correct and understands that the figure of $20 million referred to by FundamentalVR includes committed contingent funding yet to be received by FundamentalVR. Such funding would be at the same valuation as the FundamentalVR Series B second tranche and would not affect the book value of Tern’s investment in FundamentalVR.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

AI search makes message measurement a healthcare priority

As AI changes search, healthcare companies need to know whether their messages are being seen, understood and represented correctly.

Search